He Ruohang, Han Chaoqun, Li Ying, Qian Wei, Hou Xiaohua
Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Cell Dev Biol. 2021 Jun 4;9:642948. doi: 10.3389/fcell.2021.642948. eCollection 2021.
Mesenchymal stem cells (MSCs) treatment showed promising results in inflammatory bowel disease in both rodent models and patients. Nevertheless, previous studies conducted conflicting results on preclinical tumor models treated with MSCs concerning their influence on tumor initiation and progression. This study is designed to demonstrate the role of bone marrow-derived MSCs and the potential mechanism in the colitis-associated colon cancer (CAC) model.
Bone marrow-derived MSCs were isolated from green fluorescent protein-transgenic mice, cultured, and identified by flow cytometry. Azoxymethane and dextran sulfate sodium were administrated to establish the CAC mouse model, and MSCs were infused intraperitoneally once per week. The mice were weighed weekly, and colon length, tumor number, and average tumor size were assessed after the mice were killed. MSC localization was detected by immunofluorescence staining; tumor cell proliferation and apoptosis were measured by immunohistochemistry staining of Ki-67 and terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling assay, respectively. The colonic tumor tissues were isolated for RNA-seq, and fecal samples were collected for 16S ribosomal RNA sequencing of the microbiome.
After injection intraperitoneally, MSCs migrated to the intestine and inhibited the initiation of colitis-associated colorectal cancer. This inhibition effect was marked by less weight loss, longer colon length, and reduced tumor numbers. Moreover, MSCs reduced tumor cell proliferation and induced tumor cell apoptosis. Furthermore, MSCs could inhibit chronic inflammation assessed by RNA-sequencing and promote gut microbiome normalization detected by 16S ribosomal RNA sequencing.
The results proved that MSCs could migrate to the colon, inhibit chronic inflammation, and regulate gut microbiome dysbiosis to suppress the development of CAC.
间充质干细胞(MSCs)治疗在啮齿动物模型和患者的炎症性肠病中显示出有前景的结果。然而,先前关于用MSCs治疗的临床前肿瘤模型对肿瘤起始和进展的影响的研究结果相互矛盾。本研究旨在证明骨髓来源的MSCs在结肠炎相关结肠癌(CAC)模型中的作用及潜在机制。
从绿色荧光蛋白转基因小鼠中分离、培养骨髓来源的MSCs,并通过流式细胞术进行鉴定。给予氧化偶氮甲烷和葡聚糖硫酸钠以建立CAC小鼠模型,每周一次腹腔内注入MSCs。每周称量小鼠体重,处死小鼠后评估结肠长度、肿瘤数量和平均肿瘤大小。通过免疫荧光染色检测MSCs定位;分别通过Ki-67免疫组织化学染色和末端脱氧核苷酸转移酶脱氧尿苷三磷酸缺口末端标记法检测肿瘤细胞增殖和凋亡。分离结肠肿瘤组织进行RNA测序,并收集粪便样本进行微生物组的16S核糖体RNA测序。
腹腔内注射后,MSCs迁移至肠道并抑制结肠炎相关结直肠癌的起始。这种抑制作用表现为体重减轻较少、结肠长度更长和肿瘤数量减少。此外,MSCs减少肿瘤细胞增殖并诱导肿瘤细胞凋亡。此外,MSCs可通过RNA测序抑制慢性炎症,并通过16S核糖体RNA测序促进肠道微生物组正常化。
结果证明MSCs可迁移至结肠,抑制慢性炎症,并调节肠道微生物组失调以抑制CAC的发展。